Live Breaking News & Updates on Tariq Arshad

Stay updated with breaking news from Tariq arshad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Qualigen Therapeutics' (QLGN) Novel Direct Pan-RAS Inhibitors Presented at AACR

Qualigen Therapeutics' (QLGN) Novel Direct Pan-RAS Inhibitors Presented at AACR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , John Trent , Mike Sabo , Rachel Ferril , Geoffreyj Clark , Tariq Arshad , Howard Donninger , Joe Burlison , Rob Monsen , Michael Poirier , American Association For Cancer Research , Qualigen Therapeutics Inc , Qualigen Therapeutics , Novel Direct , American Association , Cancer Research , Annual Meeting , Chief Executive , Malignant Peripheral Nerve Sheath Tumors ,

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “We continue to see cancers developing resistance to current clinical agents that tar ....

United States , University Of Louisville , San Diego , Geoff Clark , John Trent , Michael Poirier , Mike Sabo , Joe Burlison , Rob Monsen , Howard Donninger , Rachel Ferril , Tariq Arshad , Geoffreyj Clark , American Association For Cancer Research , Qualigen Therapeutics Inc , Poster Includes , Preclinical Data , Novel Direct , American Association , Cancer Research , Annual Meeting , Chief Executive , Malignant Peripheral Nerve Sheath Tumors , Qualigen Therapeutics ,